Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

David Henderson

Physician Assistant, Medical Morehead City, NC Physician Assistant

NPI 1578582912 CMS profile 10434112

505 N 35Th St, Morehead City, NC 28557

Open in the dashboard

General payments

$10,437

566 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, David Henderson of Morehead City, NC is reported in the CMS Open Payments database as having received $10,437 across 566 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 96th percentile of Physician Assistant, Medical profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,799 91
2024 General $2,395 119
2023 General $2,629 142
2022 General $1,941 122
2021 General $1,673 92

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • David Henderson
  • Physician Assistant, Medical median
  • Middle half of Physician Assistant, Medical
  • National median

In program year 2025, general payments to David Henderson were reported at $1,799. Among 16,675 Physician Assistant, Medical profiles paid that year, the median was $214 and the middle half received between $62 and $755.

Show as a table
Year David Henderson Physician Assistant, Medical median Middle half National median
2019 $0 $61 $19–$193 $163
2020 $0 $20 $14–$64 $114
2021 $1,673 $156 $41–$563 $132
2022 $1,941 $185 $55–$649 $149
2023 $2,629 $199 $58–$717 $160
2024 $2,395 $206 $62–$740 $164
2025 $1,799 $214 $62–$755 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $1,285 98 payments
  2. Novo Nordisk Inc $1,204 67 payments
  3. AstraZeneca Pharmaceuticals LP $1,188 25 payments
  4. Amgen Inc. $1,161 74 payments
  5. Lilly USA, LLC $681 57 payments
  6. GlaxoSmithKline, LLC. $597 35 payments
  7. Abbott Laboratories $489 22 payments
  8. Pfizer Inc. $421 21 payments
  9. Merck Sharp & Dohme Corporation $247 16 payments
  10. Bayer HealthCare Pharmaceuticals Inc. $242 8 payments
  11. Other $2,923 143 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $10,437 566 payments
Products named General payments · program years 2021–2025
  1. FARXIGA $809 12 payments
  2. Wegovy $761 35 payments
  3. BREZTRI $592 11 payments
  4. EVENITY $526 34 payments
  5. VRAYLAR $517 29 payments
  6. Repatha $507 31 payments
  7. UBRELVY $497 43 payments
  8. QULIPTA $442 45 payments
  9. Otezla $435 33 payments
  10. MOUNJARO $393 35 payments
  11. Other $8,570 494 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 140 drugs

Part D claims

7,751

Median for Physician Assistant: 241

Drug cost

$632,207

Median for Physician Assistant: $4,110

Branded share of claims

23.9%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ozempic Semaglutide Brand 109 $111,588
Eliquis Apixaban Brand 95 $76,873
Jardiance Empagliflozin Brand 61 $57,443
Farxiga Dapagliflozin Propanediol Brand 85 $55,734
Mounjaro Tirzepatide Brand 39 $53,200
Tresiba Flextouch U-200 Insulin Degludec Brand 17 $35,672
Trulicity Dulaglutide Brand 25 $35,318
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 33 $24,558
Breztri Aerosphere Budesonide/Glycopyr/Formoterol Brand 20 $20,427
Repatha Sureclick Evolocumab Brand 14 $17,041

The 10 drugs with the highest cost, of 140 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 57 billing codes

Paid by Medicare

$76,153

Of which drugs: $9,613

Medicare patients

329

Average age 74

Services billed

2,223

172 women, 157 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 40%
Diabetes 31%
Chronic kidney disease 27%
Depression 24%
Ischemic heart disease 22%
Atrial fibrillation 19%
COPD 18%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 13 14 $8

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 31 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Wegovy
  • Novo Nordisk Inc $253
$253 — —
VRAYLAR
  • AbbVie, Inc. $207
$207 — —
FARXIGA
  • AstraZeneca Pharmaceuticals LP $201
$201 85 —
EVENITY
  • Amgen Inc. $166
$166 — —
VOQUEZNA
  • Phathom Pharmaceuticals, Inc. $158
$158 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 31 with Patron

Records

566 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant, Medical in North Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record